Pharma Mar SA (PHMMF)
86.26
-0.10
(-0.12%)
USD |
OTCM |
Dec 10, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.480B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 7.46% |
| Valuation | |
| PE Ratio | 40.48 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.636 |
| Price to Book Value | 6.379 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.9207 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2548 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.44% |
Profile
| Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain. |
| URL | http://www.pharmamar.com |
| Investor Relations URL | https://pharmamar.com/investors-2/?lang=en |
| HQ State/Province | Madrid |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 25, 2025 |
Ratings
Profile
| Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain. |
| URL | http://www.pharmamar.com |
| Investor Relations URL | https://pharmamar.com/investors-2/?lang=en |
| HQ State/Province | Madrid |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 25, 2025 |